Spots Global Cancer Trial Database for Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.
Official Title: A Randomized, Open-label Study to Evaluate the Safety and Efficacy of GX-188E, a DNA Therapeutic Vaccine Administered Intramuscularly by Electroporation, With GX-I7 Intravaginal Application or Imiquimod Topical Application in HPV16 and/or 18 Positive Patients With CIN3.
Study ID: NCT03206138
Conditions
Study Description
Brief Summary: This is a study to investigate the safety and efficacy of GX-188E administered IM plus local administration of GX-I7 or Imiquimod at cervix in subjects with cervical intraepithelial neoplasia (CIN) 3.
Detailed Description:
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Seoul St. Mary's hospital, Seoul, , Korea, Republic of
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
